MOLECULAR PARTNERS AG

PDF Zurich-Schlieren, Switzerland, June 15, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares (“ADSs”) at a public offering price of $21.25 per ADS, … Continue reading "Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States" The post Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States appeared first on Molecular Partners.

PDF Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19 Ensovibep receives U.S. FDA Fast Track Designation for the treatment of COVID-19 in both hospitalized and ambulatory settings Zurich-Schlieren, Switzerland, June 13, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built … Continue reading "Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep" The post Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep appeared first on Molecular Partners.

PDF Zurich-Schlieren, Switzerland, June 9, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares (“ADSs”) pursuant to a registration statement on Form F-1 … Continue reading "Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States" The post Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States appeared first on Molecular Partners.

PDF EMPATHY global multi-center Phase 2 – 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted an option from Molecular Partners to in-license … Continue reading "Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19" The post Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 appeared first on Molecular Partners.

PDF in vitro studies show ensovibep (MP0420) maintains full potency against the known mutations of SARS-CoV-2, including those present in variants first identified in Brazil, California, India, and New York, in addition to the previously reported variants originating from the UK and South Africa Ongoing Phase 2 pilot study of ensovibep in ambulatory patients now expanding … Continue reading "Molecular Partners’ COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants in vitro" The post Molecular Partners’ COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants in vitro appeared first on Molecular Partners.

PDF Zurich-Schlieren, Switzerland, May 04, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. “Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with … Continue reading "Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline" The post Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline appeared first on Molecular Partners.

PDF Zurich-Schlieren, Switzerland, April 23, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public … Continue reading "Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States" The post Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States appeared first on Molecular Partners.

PDF Zurich-Schlieren, Switzerland, April 21, 2021. At today’s AGM of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority. In light of the current … Continue reading "Shareholders of Molecular Partners AG Approve all Board Proposals at the Annual General Meeting; Agnete Fredriksen and Dominik Höchli elected new Board Members" The post Shareholders of Molecular Partners AG Approve all Board Proposals at the Annual General Meeting; Agnete Fredriksen and Dominik Höchli elected new Board Members appeared first on Molecular Partners.

PDF Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression. Clinical trials expected to initiate in the second half of 2021 Effector control technologies give … Continue reading "Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR" The post Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR appeared first on Molecular Partners.

PDF First study of ensovibep in patients with symptomatic COVID-19 disease Designed to evaluate dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep Ensovibep is additionally planned to be tested in two global, placebo controlled, double blinded trials: A Phase 2-3 trial in an ambulatory patient setting (named EMPATHY), and a Phase 3 trial in … Continue reading "Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients" The post Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients appeared first on Molecular Partners.